{"entity":{"id":"nct05951959","kind":"trial","name":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma","aka":["TrAVeRse"],"tldr":"A phase 2 trial of Acalabrutinib, Venetoclax, Rituximab in mantle cell lymphoma, run by AstraZeneca, active and no longer recruiting.","summary":"A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT05951959 by AstraZeneca, with 108 participants enrolled, started 2023-12-13 and due to reach its primary completion in 2028-10-31. Interventions recorded: Acalabrutinib, Venetoclax, Rituximab. Conditions listed: Mantle Cell Lymphoma (MCL). No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05951959","url":"https://clinicaltrials.gov/study/NCT05951959"}],"tags":["ctgov-ingest"],"related":[],"cancers":["mantle-cell-lymphoma"],"sections":[],"technologies":["bcl2-inhibitors","kinase-inhibitors","monoclonal-antibody"],"targets":[],"drugs":["acalabrutinib","venetoclax","rituximab"],"companies":["astrazeneca"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05951959","phase":"2","setting":"A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination With Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)","sponsor":"AstraZeneca","started":"2023-12-13","startedType":"actual","enrolled":108,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05951959/","neighbours":{"cancer":[{"id":"mantle-cell-lymphoma","kind":"cancer","name":"Mantle cell lymphoma","route":"/cancers/mantle-cell-lymphoma/"}],"technology":[{"id":"bcl2-inhibitors","kind":"technology","name":"BCL-2 inhibitors","route":"/technologies/bcl2-inhibitors/"},{"id":"monoclonal-antibody","kind":"technology","name":"Monoclonal antibodies","route":"/technologies/monoclonal-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"acalabrutinib","kind":"drug","name":"Acalabrutinib","route":"/drugs/acalabrutinib/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"}]}}